<DOC>
	<DOCNO>NCT01079104</DOCNO>
	<brief_summary>Patients hepatic dysfunction know high mortality rate . Hepa Wash ( R ) newly develop liver renal support system base use recycle albumin dialysate . The new system show high detoxification capacity in-vitro preclinical study . The aim study evaluate safety efficacy Hepa Wash system patient hepatic dysfunction intensive care unit .</brief_summary>
	<brief_title>Hepa Wash Treatment Patients With Hepatic Dysfunction Intensive Care Units</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>1 . Bilirubin ≥ 2 mg/dl AND 2 . SOFAscore ≥ 9 calculate 12 hour initiate medical resuscitation measure AND 3 . Patient intensive care unit AND 4 . Signed informed consent patient legal representative AND 5 . Patients 18 year old AND 6 . Enrollment patient within 96 hour fulfil inclusion criterion ( 13 ) . 1 . Patient known history chronic liver disease 2 . Untreatable extrahepatic cholestasis 3 . Patient survival prognosis le 6 week chronic disease ( e.g . metastasize cancer ) acute event lead ICU admission . 4 . PaO2/FIO2 ≤ 100 mmHg 5 . Patients kidney dialysis 6 . Patients MELDscore 40 7 . Mean arterial pressure ≤ 50 mmHg despite conventional medical treatment 8 . Patient testament excludes use lifeprolonging measure 9 . Postoperative patient whose liver failure relate liver surgery 10 . Uncontrolled seizures 11 . Active uncontrolled bleed 12 . Weight ≥ 120 kg 13 . Pregnancy 14 . Patient diagnose CreutzfeldtJakob disease 15 . Participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Liver failure</keyword>
	<keyword>Hepatic insufficiency</keyword>
	<keyword>Artificial liver</keyword>
	<keyword>Albumin dialysis</keyword>
</DOC>